Incyte | INCY - 债务



金融业
股票价格
USD
资产
USD 7.34B
现金及等价物
USD 4.02B
销售成本
USD 104.5M
流动资产
USD 5.48B
流动负债
USD 1.49B
债务
USD 39.43M
EBIT
USD 344.17M
EBITDA
USD 367.97M
员工
2.62K
EPS每股收益
USD 1.81
股本和储备
USD 5.62B
销售毛利
USD 1.17B
债务利息支出
USD 569K
利息收入
USD 33.69M
贷款资金
USD 29.41M
市值
USD 24.35B
净收入
USD 303.33M
营业费用
USD 5.62B
营业利润
USD 324.17M
普通股股本
USD 199.95M
PE价格收益
15.35
税前利润
USD 343.6M
销售收入
USD 1.27B
销售和管理费用
USD 328.1M
股票
USD 115.62M
贸易债权人
USD 228.62M
应收帐款人
USD 1.05B


债务 更改 日
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agenus USD 35.54M 2.34M 2025-03
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Exelixis USD 169.54M 3.5M 2026-03
Gilead Sciences USD 24.94B 5M 2025-12
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MacroGenics USD 37.01M 238K 2025-09
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Novartis USD 32.02B 615M 2025-09
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03